Who owns Mozarc Medical Holding LLC (joint venture with Medtronic, Inc.)

Mozarc Medical Holding LLC (joint venture with Medtronic, Inc.) - Profile

Mozarc Medical is a kidney health technology company that launched on 1 April 2023 as an equally owned joint venture between Medtronic and DaVita, and operates from 710 Medtronic Parkway in Minneapolis, Minnesota. It was built around Medtronic's former Renal Care Solutions business, which Medtronic contributed along with that unit's leadership, while DaVita added research and development expertise and cash drawn from its experience running dialysis clinics. The company supplies renal access products and equipment for acute and chronic dialysis therapies, sells into the United States, Europe, the Middle East, Africa, Japan and Mexico, and is developing systems intended to make dialysis easier to deliver in the home.

The disclosed stakes

One row per position. Where a holder reports the same company in two share classes, both rows are shown rather than summed, because the class is part of a position's identity.

Where each figure comes from

A private stake has no ownership form behind it, so the source is always the holder's own filing or disclosure. Anything modelled says so, with the arithmetic.

• DaVita Inc., as of 31 Dec 2025. DaVita's FY2025 10-K, Note 8 (Equity method and other investments), states verbatim: 'The Company holds a 50% voting equity interest in Mozarc Medical Holding LLC (Mozarc), an independent kidney care-focused medical device company. Medtronic, Inc. holds the other 50% voting equity interest. The Company does not maintain a controlling financial interest in Mozarc and accounts for this investment on the equity method.' This is a genuine named, percentage-disclosed private joint venture, not a combined unnamed bucket, so it qualifies as a row per project rules. Mozarc's equity method investment carrying value on DaVita's balance sheet fell from $215,706 thousand at 31 Dec 2024 to $0 (exactly zero, disclosed as such) at 31 Dec 2025. The 10-K explains the mechanics: during Q4 2025 the milestones for contingent consideration (initially valued at $86,200 thousand) were determined improbable to be achieved, so the contingent consideration payable was reduced to zero, which triggered a $73,559 thousand reduction to Mozarc's equity method investment balance, 'bringing it to zero'; DaVita also recognized equity investment losses of $139,192 thousand (2025), $112,696 thousand (2024) and $59,508 thousand (2023) from its equity method investments generally, and MD&A separately attributes 'increased equity investment losses at Mozarc which included impairment and restructuring charges of $46.4 million' during 2025. The carrying value reaching zero is an ACCOUNTING outcome of cumulative equity-method losses and the contingent-consideration remeasurement exceeding DaVita's cost basis; the 10-K does not state that DaVita disposed of or reduced its 50% ownership interest, so this is treated as an active, currently-held 50% stake with a filed carrying value of exactly $0, not as an exited position (which per project rules would instead be a notes-only line with no row). The Q2 2026 10-Q (period 30 Jun 2026), the newest filing, mentions Mozarc only in MD&A prose (comparing 2025 equity investment losses at Mozarc to 2026 net gains on other investments) and does not restate or update the Note 8 balance-sheet breakdown by investee, so no fresher entity-level figure than the FY2025 10-K exists. No share count is given because Mozarc is a privately held Delaware LLC with membership/voting equity interests, not a share class comparable to DaVita's own common stock; per project rule 7, shares is left null with the real interest (50% voting equity) stated here and in pct_of_target. No formation-transaction value or acquisition cost is disclosed in either filing searched. sourcesource 2